WuXi PharmaTech Begins Construction On Manufacturing Facility In Philadelphia, Pennsylvania
The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility.
Located in the Philadelphia Navy Yard, company officials said its new facility will complement WuXi's existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in Philadelphia.
"Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster," said Dr. Ge Li, Chairman/CEO of PharmaTech.
The company said “this expansion will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. The new facility will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.”
Leonardo Wins Contract to Resupply Navy Helicopters at Santa Rosa County, Florida Air Station
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
Hot Jobs: Growing Industrial Sectors
Where to Invest in the Booming Aerospace Manufacturing Industry
2019 Auto/Aero Site Guide
What Should High-Growth Companies Look for in a Community?
A Tale of Demographics